Mylan Inc. announced yesterday that it plans to launch a generic version of Copaxone, Teva Pharmaceutical Industries Ltd. intravenous treatment for multiple sclerosis, in the second half of 2013. Mylan added that patent litigation and US Food and Drug Administration (FDA) approval of its drug are pending. In addition, the firm announced yesterday that it has entered into a facility agreement with a syndicate of banks to securitize up to $300 million of U.S. accounts receivable. The facility is committed and has a maturity of three years. View and share
Facebook comments:
Powered by Facebook Comments
Mylan will not be able to manufacture Copaxone until 2015 per most brokerage houses. The latest to say this was Meril Lynch. Get your facts in order. TEVA is the big Gorilla and will make sure of that. Buy TEVA not MYL